ArticleBMJ open2022

Nimotuzumab plus induction chemotherapy followed by radiotherapy/concurrent chemoradiotherapy plus nimotuzumab for locally advanced nasopharyngeal carcinoma: protocol of a multicentre, open-label, single-arm, prospective phase II trial.

Jing-Jing Yuan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.